evipedia.ai ← Back to Review

Audit: QRS - Devil’s Claw for Health & Longevity

Audit conducted on 21/07/2026 01:39 using AI4L / Opus 4.8

Iterations

Summary

Items Count
Total 91
Passed 85
Failed 0
N/A 6
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All QRS content traces to ER passages (benefits, risks, protocol, monitoring, interactions).
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Cautious framing preserved (e.g., “how it works is unsettled”, “may help”).
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Pregnancy remains a contraindication; no claims strengthened or softened.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Categories preserved between ER and QRS.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No citations, NCT IDs, or brand names introduced in the QRS.
1.6 The QRS does not introduce new attributions. 🟢 No new attributions present.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Tone mirrors the ER’s balanced, evidence-graded voice.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Meets tone requirement.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Presents evidence, not prescriptions.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No direct advice language.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 Information-presenting throughout.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person address.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Plain-language throughout.
2.8 Information is presented in a concise and very compact manner 🟢 Compact, single-page density.
2.9 It DOES NOT address the reader directly 🟢 No “you” language.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Framing suits the longevity-oriented audience.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Protocol/monitoring depth reflects this audience.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Not general-population framing.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Weighting reflects the target audience.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. 🟢 Uses “longevity”; no “anti-aging” phrasing.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. 🟢 Clinical register maintained; “painkillers” mirrors ER’s own established language.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified (card/section headings, gate headings, tier labels, Monitoring table column headers). 🟢 “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”, “Contraindications”, “Key Interactions”, tier labels, and “Marker/Target/Why” all intact.
3.2 All “…” from the [qrs_template] are present in the QRS. 🟢 Full span set present (header, at_a_glance, action/time sets, benefits/risks tiers, gates, markers 1–8, cadence, qualitative 1–7).
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 Unaddressed spans unchanged.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. 🟢 Empty tiers (High benefits/risks) handled via display:none per 12.5/13.5; no ER empty-state phrasing was required.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Tier and cadence labels used verbatim.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Labels faithful to the ER.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). 🟢 No emoji indicators in the QRS.
4.5 The QRS is designed to render on one A4 page. Any section with more ER content than fits is condensed by the LLM, not extended onto a second page. 🟢 Content condensed to a single page.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Metadata comment is the first element after the doctype.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. 🟢 YAML delimited by — at lines 3 and 13.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Inside an HTML comment; not rendered.
5.4 All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required by YAML. 🟢 Values trimmed; only “00:05” quoted (contains colon).
5.5 The filename of the source ER is stated as “er_filename: [er_filename]”. 🟢 er_filename: devils_claw_2026-0721-0006_Opus_ER.md.
5.6 Version of the QRS.md file used is stated as “qrs_prompt_version: [Version of QRS.md]”. 🟢 qrs_prompt_version: 26.7.02 matches prompt.
5.7 Creation date/time is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]”. 🟢 qrs_creation_date: 2026-0721-0130.
5.8 The nickname of the AI is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”. 🟢 qrs_creator_ai_nickname: Opus.
5.9 The nickname of the AI is a single word model name without version. 🟢 “Opus” is single-word.
5.10 The full name of the AI is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”. 🟢 qrs_creator_ai_fullname: Opus 4.8.
5.11 The full name consists of the nickname and version number with no additional qualifier. 🟢 “Opus 4.8” has no extra qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]”. 🟢 qrs_filename: devils_claw_2026-0721-0006_Opus_QRS.html.
5.13 All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required by YAML. 🟢 Consistent, trimmed values.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is the [canonical_topic] followed by “ - Quick Reference Sheet”, HTML-entity-encoded as needed. 🟢 “Devil’s Claw for Health & Longevity - Quick Reference Sheet”.
6.2 [header_topic] is the [canonical_topic] of the ER frontmatter, HTML entities encoded as needed. 🟢 “Devil’s Claw for Health & Longevity”.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]. 🟢 2026-0721-0130 → 07/21/2026.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname]. 🟢 “Opus 4.8”.
6.5 No additional header content appears (no badge, version stamp, AKA line, source-AI attribution, audit date, or variant marker). 🟢 Header carries only title and standard subline.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is a dense, execution-oriented summary of the ER Conclusion section. 🟢 Distilled from the Conclusion.
7.2 [at_a_glance] is no longer than 60 words. 🟢 55 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 All facts trace to Conclusion passages.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge. 🟢 Plain-language only.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values). 🟢 No trial citations.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results. 🟢 No statistics.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section. 🟢 Derived from “Populations who should avoid it”.
8.2 [stop_items] represent the Contraindications from the ER. 🟢 All six contraindications reflected.
8.3 Individual [stop_items] are formatted as <li></li>. 🟢 Each item is an <li>.
8.4 Items are as concise as possible. No trailing explanations, mechanistic rationale, or content after a dash. 🟢 Concise, no trailing clauses.
8.5 Parenthetical qualifiers from the ER bullet ARE preserved, kept concise. 🟢 “Warfarin without INR monitoring” preserves the key qualifier.
8.6 When the ER uses ranking notation inside parens, normalize to a plain comma-separated list rather than carrying the bare symbol. N/A The ER contraindications use no ranking notation.
8.7 If no [stop_items] are present the section is left empty. N/A Contraindications are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section. 🟢 Derived from the ER interactions bullets.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any already listed as Contraindications. 🟢 Anticoagulant, NSAID, glucose-lowering, cardiac, CYP, acid-suppressing, and surgery interactions captured.
9.3 Individual [caution_items] are formatted as <li></li>. 🟢 Each item is an <li>.
9.4 Items are as concise as possible. No trailing explanations or content after a dash. 🟢 Concise, no trailing clauses.
9.5 Parenthetical qualifiers (example drug lists, time windows, etc.) ARE preserved, kept concise. 🟢 Example drugs and “stop 1–2 weeks before” preserved.
9.6 When the ER uses ranking notation inside parens, normalize to a plain comma-separated list rather than carrying the bare symbol. N/A No ranking notation used in the ER interactions.
9.7 If no [caution_items] are present the section is left empty. N/A Key interactions are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section. 🟢 Derived from the Therapeutic Protocol.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects. 🟢 Daily dose, timing/split dosing, trial duration.
10.3 If less than three distinct actionable aspects are mentioned, unused sets are left empty and invisible. N/A Three actionable aspects are present.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content from the ER Protocol. 🟢 All three action cells carry ER-derived content.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER. 🟢 Covers the two aspects the ER provides (initial relief, full trial).
11.2 The sets are picked and ordered by the magnitude of the related benefit. 🟢 Ordered initial relief → full trial.
11.3 If less than three distinct time-to-effect aspects are mentioned, unused sets are left empty and invisible. 🟢 Only two aspects exist; third set is empty and display:none.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content from the ER. 🟢 Both used sets carry ER-derived content.
11.5 If the ER does not provide any time-to-effect information, the section is removed from the Protocol Panel. N/A The ER provides time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section. 🟢 Derived directly.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]. 🟢 All four tier variables present.
12.3 Items are as concise as possible (no explanations, effect sizes, qualifiers, citations). 🟢 Concise tier lists.
12.4 Parenthetical content is stripped, NOT preserved. 🟢 “(Chondroprotection)” dropped to “cartilage protection”.
12.5 If no items of a sub-section are present the respective span is set to display:none. 🟢 benefits_high set to display:none.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section. 🟢 Derived directly.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]. 🟢 All four tier variables present.
13.3 Items are as concise as possible (no explanations, frequencies, qualifiers, citations). 🟢 Concise tier lists; “⚠️ Conflicted” qualifiers stripped.
13.4 Parenthetical content is stripped, NOT preserved. 🟢 No parentheticals carried through.
13.5 If no items of a sub-section are present the respective span is set to display:none. 🟢 risks_high set to display:none.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section. 🟢 Derived from the Monitoring Protocol table.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed. 🟢 All 8 markers (hs-CRP, ESR, glucose, HbA1c, INR, ALT/AST, eGFR/creatinine, BP & HR) with matching targets.
14.3 [monitoring_cadence] is populated with the monitoring cadence from the ER. 🟢 Cadence populated and faithful to the ER.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section. 🟢 Derived from the ER qualitative markers list.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed. 🟢 All 7 qualitative markers listed verbatim.

Issues 21/07/2026 01:39

Pass rate 100.00%. No issues found.